Latest News & Features
Europe
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK. 3 November 2014
Big Pharma
The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered. 3 November 2014
Americas
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success. 3 November 2014
Asia-Pacific
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore. 3 November 2014
Americas
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry. 3 November 2014
Americas
Canada’s highest court is set to hear a hotly anticipated dispute pitting generic company Apotex against drug companies Sanofi and Bristol-Myers Squibb (BMS). 3 November 2014
Americas
Biotechnology company Amgen has filed a lawsuit against Sanofi and Regeneron Pharmaceuticals accusing the pair of infringing three patents. 3 November 2014
Asia
Indian pharmaceutical company Intas Pharmaceuticals has been granted an injunction preventing a rival from marketing an anti-epilepsy drug it said infringed one of its trademarks. 30 October 2014
Asia
A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj. 29 October 2014
Biotechnology
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS. 29 October 2014